Columbia University Herbert Irving Comprehensive Cancer Center | Strategic Alliance Partners

December 01, 2023

Nicole Lamanna, MD, discusses how the use of novel agents could address resistance associated with current treatment options for patients with chronic lymphocytic leukemia.

November 21, 2023

Nicole Lamanna, MD, discusses the challenges of resistance in patients with CLL, highlights treatment being developed for patients who progress on BTK inhibitor– or venetoclax-based regimens, and emphasizes the need for further enrollment onto clinical trials.

November 06, 2023

Moshe Kelsen, MBA, discusses ongoing initiatives that aim to improve diversity, equity, and inclusion for patients with cancer receiving treatment at Columbia University.

August 23, 2023

Jennifer Effie Amengual, MD, discusses considerations for community oncologists looking to refer patients with relapsed/refractory follicular lymphoma (FL) to the ongoing second-line, phase 3 SYMPHONY-1 trial (NCT04224493).

August 17, 2023

Jennifer Effie Amengual, MD, discusses unmet needs in FL that SYMPHONY-1 aims to address; the potential benefits of tazemetostat plus lenalidomide and rituximab in patients who are refractory to rituximab or who relapse within 24 months of their initial therapy; and where this regimen may fit into the relapsed/refractory FL treatment paradigm alongside investigative CAR T-cell therapies.

June 07, 2023

In this sixth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, shares future considerations for optimizing the identification of Lynch syndrome and other efforts underway to prevent colorectal cancer in those who have this condition.

May 31, 2023

In this fifth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, highlights progress made with regard to colon cancer treatment and Lynch syndrome, including leveraging immunotherapy.

May 24, 2023

In this fourth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, explains the implications of Lynch syndrome genotype on risk of colorectal cancer.

May 17, 2023

In this third episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, discusses testing guidance for identifying Lynch syndrome.

May 16, 2023

Brian Henick, MD, discusses the 3-year updated data from a phase 2 trial investigating treatment with neoadjuvant atezolizumab plus chemotherapy in patients with resectable non–small cell lung cancer.

May 10, 2023

In this second episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, delves into the epidemiology of Lynch syndrome, the pathogenic variants in the mismatch-repair genes that cause the condition, and criteria utilized to identify it.

May 03, 2023

In this first episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, provides a brief overview of Lynch syndrome and its prevalence in the United States and beyond.

April 25, 2023

Adana A.M. Llanos, PhD, MPH, discusses the relationship between prediagnostic allostatic load and breast cancer clinicopathology in Black women.

April 14, 2023

Julia E. McGuinness, MD, discusses the rationale for combining this novel PI3K inhibitor with fulvestrant and emphasized the importance of developing increasingly mutant-specific PI3K inhibitors in hormone receptor–positive breast cancer.

March 22, 2023

Brian Henick, MD, discusses the different ways to identify biomarkers of immunotherapy response in patients with lung cancer and how refining these approaches may improve individualized treatment approaches in the future.

March 20, 2023

Brian Henick, MD, discusses the importance of further exploring biomarkers in the immune microenvironment for immunotherapy in patients with lung cancer.

February 16, 2023

Drs Flinn, Lamanna, Brown, and Tam discuss the FDA approval of zanubrutinib in chronic lymphocytic leukemia and small lymphocytic lymphoma.

February 07, 2023

Lamanna discussed key efficacy and safety data with zanubrutinib from the SEQUOIA and ALPINE trials, the advantages of zanubrutinib compared with previous therapeutic options, and how the approval of the agent will affect the use of next-generation BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma .

December 23, 2022

Richard D. Carvajal, MD, discusses the implications of the FDA approval of tebentafusp in uveal melanoma, the possibility of exploring tebentafusp in other HLA subtypes, and other areas of intriguing research in uveal melanoma.

December 13, 2022

Ran Reshef, MD, discusses findings from the phase 3 BMT CTN 1703 trial examining graft-vs-host disease prophylaxis in reduced intensity conditioning.